Stock Events

Stock Events

Verrica Pharmaceuticals 

$7.18
30
+$0.02+0.28% Today

Statistics

Day High
7.4
Day Low
6.95
52W High
8.87
52W Low
3.28
Volume
139,291
Avg. Volume
-
Mkt Cap
68.14M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.26
-0.83
-0.41
0.02
Expected EPS
-0.45382
Actual EPS
N/A

Financials

-1,012.15%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
15.13MRevenue
-153.16MNet Income

Analyst Ratings

17Average Price Target
The highest estimate is 17.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRCA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AnaptysBio
ANAB
Mkt Cap1.94B
AnaptysBio, Inc. focuses on developing antibody-based therapies for dermatological conditions, directly competing with Verrica's dermatology products.
Journey Medical
DERM
Mkt Cap172.6M
Journey Medical Corporation is directly involved in dermatology, marketing products that compete in the same space as Verrica's treatments for skin conditions.
Bausch Health Companies
BHC
Mkt Cap2.11B
Bausch Health Companies Inc. has a broad portfolio in dermatology, offering products that compete with Verrica's skin treatment solutions.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has a diverse range of healthcare products, including treatments for dermatological conditions, making it a competitor in the dermatology market.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, offers products for skin health, competing in the same market as Verrica.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie Inc. has a strong presence in dermatology with its Humira product and others, competing in the same therapeutic areas as Verrica.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. develops treatments for various conditions, including skin diseases, making it a competitor in the dermatology space.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline plc has a portfolio that includes treatments for skin conditions, competing with Verrica's dermatological products.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. offers a range of healthcare products, including treatments for skin conditions, making it a competitor in the dermatology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments in dermatology, directly competing with Verrica Pharmaceuticals in the development of skin disease treatments.

About

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Show more...
CEO
Dr. Jayson M. Rieger M.B.A., Ph.D.
Employees
71
Country
United States
ISIN
US92511W2070

Listings

F
DE
1NE0.F
XNAS
US
VRCA
STU
DE
1NE0.STU
MU
DE
1NE0.MU

0 Comments

Share your thoughts

FAQ

What is Verrica Pharmaceuticals stock price today?▼
The current price of VRCA is $7.18 USD — it has increased by +0.28% in the past 24 hours. Watch Verrica Pharmaceuticals stock price performance more closely on the chart.
What is Verrica Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Verrica Pharmaceuticals stocks are traded under the ticker VRCA.
Is Verrica Pharmaceuticals stock price growing?▼
VRCA stock has risen by +9.19% compared to the previous week, the month change is a +20.15% rise, over the last year Verrica Pharmaceuticals has showed a +59.6% increase.
What is Verrica Pharmaceuticals market cap?▼
Today Verrica Pharmaceuticals has the market capitalization of 68.14M
When is the next Verrica Pharmaceuticals earnings date?▼
Verrica Pharmaceuticals is going to release the next earnings report on May 12, 2026.
What were Verrica Pharmaceuticals earnings last quarter?▼
VRCA earnings for the last quarter are -0.57 USD per share, whereas the estimation was -0.7 USD resulting in a +18.86% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Verrica Pharmaceuticals revenue for the last year?▼
Verrica Pharmaceuticals revenue for the last year amounts to 15.13M USD.
What is Verrica Pharmaceuticals net income for the last year?▼
VRCA net income for the last year is -153.16M USD.
How many employees does Verrica Pharmaceuticals have?▼
As of May 06, 2026, the company has 71 employees.
In which sector is Verrica Pharmaceuticals located?▼
Verrica Pharmaceuticals operates in the Health & Wellness sector.
When did Verrica Pharmaceuticals complete a stock split?▼
The last stock split for Verrica Pharmaceuticals was on July 25, 2025 with a ratio of 1:10.
Where is Verrica Pharmaceuticals headquartered?▼
Verrica Pharmaceuticals is headquartered in West Chester, United States.